TRIAL OF PACLITAXEL AND CARBOPLATIN VERSUS COMBINATIONS IN PATIENTS WITH CANCER

紫杉醇和卡铂与联合用药在癌症患者中的试验

• 批准号: 7376348
• 负责人: PUI CHUN CHENG
• 金额: $ 0.23万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376348
• 关键词: TRIAL; PACLITAXEL; CARBOPLATIN; VERSUS; COMBINATIONS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ovarian cancer and primary peritoneal cancer strikes over 20,000 women each year in the United States. Most women present with advanced disease. Those with advanced disease will have higher rates of relapse or persistent disease. The standard drug treatment following surgery is with two platinum-based drugs (Carboplatin, paclitaxel, and more recently cisplatin). Despite recent improvement in management, a significant number of patients, approximately 25% will have a recurrence of their cancer. Thus, the challenge is to find an optimal treatment regimen agent(s) that will improve overall survival, and decrease the percentage of recurrence. There are three new drugs which have been shown to be successful in the treatment of ovarian and peritoneal cancer. These drugs are Gemcitabene, Topotecan and Doxil given alone or in combination with the standard treatments. This study will look at the effectiveness of adding one of these drugs to the standard drug regimen of Carboplatin or Paclitaxel. Studies have shown that ovarian cancer can run in families. BRCA 1 and BRCA 2 are two genes that have been found in the blood or tumors of these women. It is possible that these women may respond differently to chemotherapy treatment than women who do not have one of these genes. Therefore, a second purpose of this study is to look at whether there is a difference in survival in women who have these genes. Blood and tumor tissue will be analyzed in order to identify these patients in the study who have these genes and compare them to women who do not. This study will also look at the side effects associated with the new combinations compared to the standard treatments.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。在美国，每年有超过2万名女性患卵巢癌和原发性腹膜癌。大多数妇女表现为疾病晚期。那些疾病晚期的患者将有更高的复发率或持续性疾病。手术后的标准药物治疗是两种铂类药物（卡铂、紫杉醇和最近的顺铂）。尽管最近治疗有所改善，但仍有相当数量的患者，大约25%的患者会复发。因此，我们面临的挑战是找到一种最佳的治疗方案，既能提高总生存率，又能降低复发率。有三种新药在治疗卵巢癌和腹膜癌方面已被证明是成功的。这些药物是吉西他滨，拓扑替康和Doxil单独或与标准治疗联合使用。这项研究将着眼于将这些药物中的一种添加到卡铂或紫杉醇的标准药物方案中的有效性。研究表明，卵巢癌可以在家族中遗传。brca1和brca2是在这些女性的血液或肿瘤中发现的两个基因。这些女性对化疗的反应可能与没有这些基因的女性不同。因此，这项研究的第二个目的是观察拥有这些基因的女性在生存方面是否有差异。将对血液和肿瘤组织进行分析，以确定研究中具有这些基因的患者，并将其与没有这些基因的女性进行比较。这项研究还将研究与标准治疗相比较的新组合的副作用。